CoChat
Sign Up
Cited by 301Memory and Neural MechanismsStress Responses and CortisolMemory Processes and Influences

The DOI matches its Crossref record; 86 of the 87 references it cites were found in a registry or an index.

Glucocorticoid Effects on Memory Retrieval Require Concurrent Noradrenergic Activity in the Hippocampus and Basolateral Amygdala

Open access
Roozendaal, Benno, Hahn, Emily L., Nathan, Sheila V., de Quervain, Dominique J.-F., McGaugh, James L.·2004·The Journal of Neuroscience
DOI 10.1523/jneurosci.2574-04.2004PMC PMC6729799
Open this paper in CoChat — free accountOpen PDF

Abstract

Previous findings indicate that administration of aβ-adrenoceptor antagonist systemically blocks glucocorticoid impairment of memory retrieval. Here, we report that β-adrenoceptor activation in the hippocampus and the basolateral complex of the amygdala (BLA) is implicated in the impairing effects of glucocorticoids on memory retrieval. The specific glucocorticoid receptor (GR) agonist 11β,17β-dihydroxy-6,21-dimethyl-17α-pregna-4,6-trien-20yn-3-one (RU 28362) (15 ng) infused into the hippocampus of male Sprague Dawley rats 60 min before water maze retention testing, 24 hr after training, impaired probe trial retention performance, as assessed by quadrant search time and initial latency to cross the platform location. Because we found previously that RU 28362 infused into the hippocampus does not affect water maze acquisition or immediate recall, the findings suggest that the GR agonist-induced retention impairment was attributable to a selective influence on long-term memory retrieval. Likewise, systemic injections of the β 1-adrenoceptor partial agonist xamoterol (3.0 or 10.0 mg/kg, s.c.) 60 min before the probe trial dose-dependently impaired retention performance. The β-adrenoceptor antagonist propranolol (2.0 mg/kg) administered subcutaneously before retention testing did not affect retention performance alone, but blocked the memory retrieval impairment induced by concurrent intrahippocampal infusions of RU 28362. Pretest infusions of the β 1-adrenoceptor antagonist atenolol into either the hippocampus (1.25 μg in 0.5 μl) or the BLA (0.5 μg in 0.2 μl) also prevented the GR agonist-induced memory retrieval impairment. These findings suggest that glucocorticoids impair retrieval of long-term spatial memory by facilitating noradrenergic mechanisms in the hippocampus, and additionally, that norepinephrine-mediated BLA activity is critical in enabling hippocampal glucocorticoid effects on memory retrieval.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.2574-04.2004

Cites

86 of 86 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Representative photomicrographs illustrating placement of cannula and needle tip in the dorsal hippocampus ( A ) and the BLA ( B ). Arrow points to needle tip. CA1, CA3, Ammon's horn; CEA, central nucleus of the amygdala; DG, dentate gyrus; LA, lateral nucleus of the amygdala; 3V, third ventricle.
Figure 1 Representative photomicrographs illustrating placement of cannula and needle tip in the dorsal hippocampus ( A ) and the BLA ( B ). Arrow points to needle tip. CA1, CA3, Ammon's horn; CEA, central nucleus of the amygdala; DG, dentate gyrus; LA, lateral nucleus of the amygdala; 3V, third ventricle.CC-BY-NC-SA · From the PDF
Image 2
CC-BY-NC-SA · From the PDF
Figure 2 The 𝛃 -adrenoceptor antagonist propranolol (2.0 mg/kg) administered subcutaneously75minbeforeretentiontestingblockedtheimpairingeffectsinducedbytheGRagonist RU 28362 (15 ng in 0.5 𝛍 l) infused into the hippocampus 60 min before retention testing on probetrialretentionperformanceinawatermaze. A , Time spent in the training (T) and opposite (O) quadrants (mean + SEM) in seconds during the 60 sec probe trial. B , Latencies (mean + SEM) in seconds to cross the platform location. C , Representative probe trial swim paths. S indicates start. * p < 0.05, ** p < 0.01 compared with the corresponding vehicle group; ◆ p < 0.05, ◆◆ p < 0.01 compared with the saline-RU 28362 group; F p < 0.05, FF p < 0.01 compared with the training quadrant ( n = 13-17 per group).
Figure 2 The 𝛃 -adrenoceptor antagonist propranolol (2.0 mg/kg) administered subcutaneously75minbeforeretentiontestingblockedtheimpairingeffectsinducedbytheGRagonist RU 28362 (15 ng in 0.5 𝛍 l) infused into the hippocampus 60 min before retention testing on probetrialretentionperformanceinawatermaze. A , Time spent in the training (T) and opposite (O) quadrants (mean + SEM) in seconds during the 60 sec probe trial. B , Latencies (mean + SEM) in seconds to cross the platform location. C , Representative probe trial swim paths. S indicates start. * p < 0.05, ** p < 0.01 compared with the corresponding vehicle group; ◆ p < 0.05, ◆◆ p < 0.01 compared with the saline-RU 28362 group; F p < 0.05, FF p < 0.01 compared with the training quadrant ( n = 13-17 per group).CC-BY-NC-SA · From the PDF
Figure 3 The 𝛃 1 -adrenoceptor antagonist atenolol (1.25 𝛍 g in 0.5 𝛍 l) administered into the hippocampus 60 min before retention testing blocked the impairing effects induced by coadministration of the GR agonist RU 28362 (15 ng) on probe trial retention performance in a water maze. A , Time spent in the training (T) and opposite (O) quadrants (mean + SEM) in seconds during the 60 sec probe trial. B , Latencies (mean + SEM) in seconds to cross the platform location. * p < 0.05, ** p < 0.01 compared with the corresponding vehicle group; ◆ p < 0.05, ◆◆ p < 0.01comparedwiththeRU28362group; FF p < 0.01comparedwiththe training quadrant ( n = 11-13 per group).
Figure 3 The 𝛃 1 -adrenoceptor antagonist atenolol (1.25 𝛍 g in 0.5 𝛍 l) administered into the hippocampus 60 min before retention testing blocked the impairing effects induced by coadministration of the GR agonist RU 28362 (15 ng) on probe trial retention performance in a water maze. A , Time spent in the training (T) and opposite (O) quadrants (mean + SEM) in seconds during the 60 sec probe trial. B , Latencies (mean + SEM) in seconds to cross the platform location. * p < 0.05, ** p < 0.01 compared with the corresponding vehicle group; ◆ p < 0.05, ◆◆ p < 0.01comparedwiththeRU28362group; FF p < 0.01comparedwiththe training quadrant ( n = 11-13 per group).CC-BY-NC-SA · From the PDF
Figure4 The 𝛃 1 -adrenoceptorantagonistatenolol(0.5 𝛍 gin0.2 𝛍 l) administered into the BLA60minbeforeretention testing blocked the impairing effects induced by the GR agonist RU 28362(15ngin0.5 𝛍 l) infused into the hippocampus 60 min before retention testing on probe trial retention performance in a water maze. A , Time spent in the training (T) and opposite (O) quadrants (mean + SEM) in seconds during the 60 sec probe trial. B , Latencies (mean + SEM) in seconds to cross the platform location. * p < 0.05, ** p < 0.01 compared with the correspondingvehiclegroup; ◆◆ p < 0.01comparedwiththesaline-RU28362group; FF p < 0.01 compared with the training quadrant ( n = 9-12 per group).
Figure4 The 𝛃 1 -adrenoceptorantagonistatenolol(0.5 𝛍 gin0.2 𝛍 l) administered into the BLA60minbeforeretention testing blocked the impairing effects induced by the GR agonist RU 28362(15ngin0.5 𝛍 l) infused into the hippocampus 60 min before retention testing on probe trial retention performance in a water maze. A , Time spent in the training (T) and opposite (O) quadrants (mean + SEM) in seconds during the 60 sec probe trial. B , Latencies (mean + SEM) in seconds to cross the platform location. * p < 0.05, ** p < 0.01 compared with the correspondingvehiclegroup; ◆◆ p < 0.01comparedwiththesaline-RU28362group; FF p < 0.01 compared with the training quadrant ( n = 9-12 per group).CC-BY-NC-SA · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 87 references

Research works printed but not linked: 8

  1. 1991, Front Neuroendocrinol, 12, 95
  2. 1978, Behav Biol, 25, 509
  3. 1988, Acta Psychiatr Scand, 341, 138
  4. 1995, Chin J Physiol, 38, 81
  5. 10.1037/0735-7044.106.1.62 · DOI
  6. 10.1210/me.15.4.553 · DOI
  7. 10.1037/0735-7044.114.6.1088 · DOI
  8. 10.1037/0735-7044.115.5.1002 · DOI

Cited by

Sorted by citations

See all 301

Related

Metadata

Authors
Roozendaal, B., Hahn, E. L., Nathan, S. V., de Quervain, D. J.-F., & McGaugh, J. L.
Affiliations
  • University of California, Irvine (US)
  • University of Zurich (CH)
ORCID
Venue
The Journal of Neuroscience
Publisher
Society for Neuroscience
Published
2004-09-15
Volume
24
Issue
37
Pages
8161-8169
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
DOI
10.1523/jneurosci.2574-04.2004
PMC
PMC6729799
OpenAlex
W2050582843
Cited by
301
References
87
Citations by year
2026: 3 · 2025: 2 · 2024: 6 · 2023: 5 · 2022: 6 · 2021: 2 · 2020: 9 · 2019: 10 · 2018: 16 · 2017: 13 · 2016: 21 · 2015: 19 · 2014: 20 · 2013: 17 · 2012: 20
FWCI
8.58
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
  • National Science Foundation
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (58420)
  • U.S. Public Health Service
  • National Institute of Mental Health (R01MH012526, MH12526, R56MH012526)
Topics
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Memory and Neural Mechanisms
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Memory Processes and Influences
Keywords
glucocorticoids, memory retrieval, noradrenergic activity, hippocampus, basolateral amygdala, beta-adrenergic receptors, glucocorticoid receptor, RU 28362, xamoterol, propranolol, atenolol, spatial memory, water maze, long-term memory, norepinephrine
MeSH terms
Adrenergic beta-Antagonists, Amygdala, Androstanols, Animals, Atenolol, Corticosterone, Emotions, Escape Reaction, Hippocampus, Hormone Antagonists, Male, Propranolol, Reaction Time, Mental Recall, Receptors, Glucocorticoid, Stress, Psychological, Rats, Sprague-Dawley, Xamoterol, Receptors, Adrenergic, beta-1, Receptors, Adrenergic, beta-2, Maze Learning, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review